Biotech Stock News (RXII) (FPRX) (BMY) (ZFGN)

Rxi Pharmaceuticals (NASDAQ:RXII) On October 15, 2015 Rxi Pharmaceuticals announced positive phase 2a results for its RXI-109 compound. The trial, known as RXI-109-1402, was comparing RXI-109 treated scars against scars that were revised by surgery — control group. To test out dosing though Rxi gave one cohort of patients 5 mg/cm of RXI-109 while another … Read more

Biotech Stock News (RGLS)(AZN)(INO)(TKMR)

Regulus Therapeutics (NASDAQ:RGLS) & AstraZeneca (NYSE:AZN)  On April 7, 2015 Shares of Regulus were up about 8% in after hours trading after the company reported that Astrazeneca would like to collaborate with the company to develop a NASH drug. NASH stands for non-alcoholic steatohepatitis and as the name suggests it is a disease that doesn’t … Read more